Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
accepted:
17
03
2021
pubmed:
30
3
2021
medline:
1
2
2022
entrez:
29
3
2021
Statut:
ppublish
Résumé
Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, making it hard for clinicians to be informed on plausible treatment courses. Our objective was to assess, under real-world clinical circumstances, LAI discontinuation rates over a period of 12 months after a first prescription, reasons for discontinuation, and associated factors. The STAR Network 'Depot Study' was a naturalistic, multicentre, observational prospective study that enrolled subjects initiating a LAI without restrictions on diagnosis, clinical severity or setting. Participants from 32 Italian centres were assessed at baseline and at 6 and 12 months of follow-up. Psychopathology, drug attitude and treatment adherence were measured using the Brief Psychiatric Rating Scale, the Drug Attitude Inventory and the Kemp scale, respectively. The study followed 394 participants for 12 months. The overall discontinuation rate at 12 months was 39.3% (95% confidence interval [CI] 34.4-44.3), with paliperidone LAI being the least discontinued LAI (33.9%; 95% CI 25.3-43.5) and olanzapine LAI the most discontinued (62.5%; 95% CI 35.4-84.8). The most frequent reason for discontinuation was onset of adverse events (32.9%; 95% CI 25.6-40.9) followed by participant refusal of the medication (20.6%; 95% CI 14.6-27.9). Medication adherence at baseline was negatively associated with discontinuation risk (hazard ratio [HR] 0.853; 95% CI 0.742-0.981; p = 0.026), whereas being prescribed olanzapine LAI was associated with increased discontinuation risk compared with being prescribed paliperidone LAI (HR 2.156; 95% CI 1.003-4.634; p = 0.049). Clinicians should be aware that LAI discontinuation is a frequent occurrence. LAI choice should be carefully discussed with the patient, taking into account individual characteristics and possible obstacles related to the practicalities of each formulation.
Sections du résumé
BACKGROUND
Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, making it hard for clinicians to be informed on plausible treatment courses.
OBJECTIVE
Our objective was to assess, under real-world clinical circumstances, LAI discontinuation rates over a period of 12 months after a first prescription, reasons for discontinuation, and associated factors.
METHODS
The STAR Network 'Depot Study' was a naturalistic, multicentre, observational prospective study that enrolled subjects initiating a LAI without restrictions on diagnosis, clinical severity or setting. Participants from 32 Italian centres were assessed at baseline and at 6 and 12 months of follow-up. Psychopathology, drug attitude and treatment adherence were measured using the Brief Psychiatric Rating Scale, the Drug Attitude Inventory and the Kemp scale, respectively.
RESULTS
The study followed 394 participants for 12 months. The overall discontinuation rate at 12 months was 39.3% (95% confidence interval [CI] 34.4-44.3), with paliperidone LAI being the least discontinued LAI (33.9%; 95% CI 25.3-43.5) and olanzapine LAI the most discontinued (62.5%; 95% CI 35.4-84.8). The most frequent reason for discontinuation was onset of adverse events (32.9%; 95% CI 25.6-40.9) followed by participant refusal of the medication (20.6%; 95% CI 14.6-27.9). Medication adherence at baseline was negatively associated with discontinuation risk (hazard ratio [HR] 0.853; 95% CI 0.742-0.981; p = 0.026), whereas being prescribed olanzapine LAI was associated with increased discontinuation risk compared with being prescribed paliperidone LAI (HR 2.156; 95% CI 1.003-4.634; p = 0.049).
CONCLUSIONS
Clinicians should be aware that LAI discontinuation is a frequent occurrence. LAI choice should be carefully discussed with the patient, taking into account individual characteristics and possible obstacles related to the practicalities of each formulation.
Identifiants
pubmed: 33779944
doi: 10.1007/s40263-021-00809-w
pii: 10.1007/s40263-021-00809-w
pmc: PMC8219561
doi:
Substances chimiques
Antipsychotic Agents
0
Delayed-Action Preparations
0
Types de publication
Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
655-665Références
Bowtell M, Ratheesh A, McGorry P, Killackey E, O’Donoghue B. Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review. Schizophr Res. 2018;197:9–18. https://doi.org/10.1016/j.schres.2017.11.010 .
doi: 10.1016/j.schres.2017.11.010
pubmed: 29146020
Taylor DM, Velaga S, Werneke U. Reducing the stigma of long acting injectable antipsychotics—current concepts and future developments. Nord J Psychiatry. 2018;72(sup1):S36–9. https://doi.org/10.1080/08039488.2018.1525638 .
doi: 10.1080/08039488.2018.1525638
pubmed: 30688170
Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3–78. https://doi.org/10.1177/0269881119889296 .
doi: 10.1177/0269881119889296
pubmed: 31829775
Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410–72. https://doi.org/10.1177/0004867416641195 .
doi: 10.1177/0004867416641195
pubmed: 27106681
NICE. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. 2014. https://www.nice.org.uk/guidance/cg178 . Accessed 1 Sept 2020.
SIGN. Management of schizophrenia. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2013.
Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19(1):3–5. https://doi.org/10.1017/s1092852913001016 .
doi: 10.1017/s1092852913001016
pubmed: 24512639
Stevens GL, Dawson G, Zummo J. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Interv Psychiatry. 2016;10(5):365–77. https://doi.org/10.1111/eip.12278 .
doi: 10.1111/eip.12278
pubmed: 26403538
Lindenmayer JP, Glick ID, Talreja H, Underriner M. Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of Schizophrenia. J Clin Psychopharmacol. 2020;40(4):346–9. https://doi.org/10.1097/jcp.0000000000001225 .
doi: 10.1097/jcp.0000000000001225
pubmed: 32639287
Zhao YJ, Lin L, Teng M, Khoo AL, Soh LB, Furukawa TA, et al. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open. 2016;2(1):59–66. https://doi.org/10.1192/bjpo.bp.115.002576 .
doi: 10.1192/bjpo.bp.115.002576
pubmed: 27703755
pmcid: 4995551
Kishimoto T, Hagi K, Nitta M, Leucht S, Olfson M, Kane JM, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603–19. https://doi.org/10.1093/schbul/sbx090 .
doi: 10.1093/schbul/sbx090
pubmed: 29868849
Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol. 2000;20(6):699–702. https://doi.org/10.1097/00004714-200012000-00019 .
doi: 10.1097/00004714-200012000-00019
pubmed: 11106145
Davis JM, Metalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs. 1994;47(5):741–73. https://doi.org/10.2165/00003495-199447050-00004 .
doi: 10.2165/00003495-199447050-00004
pubmed: 7520856
Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar I disorder: a real-world study using US claims data. Adv Ther. 2018;35(10):1612–25. https://doi.org/10.1007/s12325-018-0785-y .
doi: 10.1007/s12325-018-0785-y
pubmed: 30206822
pmcid: 6182631
Iwata N, Inagaki A, Sano H, Niidome K, Kojima Y, Yamada S. Treatment persistence between long-acting injectable versus orally administered aripiprazole among patients with schizophrenia in a real-world clinical setting in Japan. Adv Ther. 2020;37(7):3324–36. https://doi.org/10.1007/s12325-020-01396-w .
doi: 10.1007/s12325-020-01396-w
pubmed: 32500455
pmcid: 7314731
Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiat. 2017;74(7):686–93. https://doi.org/10.1001/jamapsychiatry.2017.1322 .
doi: 10.1001/jamapsychiatry.2017.1322
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9. https://doi.org/10.1016/j.jclinepi.2007.11.008 .
doi: 10.1016/j.jclinepi.2007.11.008
Ostuzzi G, Mazzi MA, Terlizzi S, Bertolini F, Aguglia A, Bartoli F, et al. Factors associated with first-versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLoS ONE. 2018;13(8):e0201371. https://doi.org/10.1371/journal.pone.0201371 .
doi: 10.1371/journal.pone.0201371
pubmed: 30071042
pmcid: 6072022
Bartoli F, Ostuzzi G, Crocamo C, Corbo M, D’Agostino A, Martinotti G, et al. Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophrenia-spectrum disorders: findings from the STAR Network Depot Study. Int Clin Psychopharmacol. 2020;35(4):214–20. https://doi.org/10.1097/yic.0000000000000317 .
doi: 10.1097/yic.0000000000000317
pubmed: 32371833
Overall J. The brief psychiatric rating scale in psychopharmacology research. In: Olivier-Martin R, editor. Pichot P. S. Karger AG; 1974. p. 67–78.
Roncone R, Tozzini C, Mazza M, de Risio A, Giosuè P, Morosini P, et al. Validation of the Italian version of the Self-report Insight Scale. Epidemiol Psichiatr Soc. 2003;12(1):63–75. https://doi.org/10.1017/s1121189x00006060 .
doi: 10.1017/s1121189x00006060
pubmed: 12723393
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187:366–71. https://doi.org/10.1192/bjp.187.4.366 .
doi: 10.1192/bjp.187.4.366
pubmed: 16199797
Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177–83. https://doi.org/10.1017/s0033291700050182 .
doi: 10.1017/s0033291700050182
pubmed: 6133297
Rossi A, Arduini L, De Cataldo S, Stratta P. Subjective response to neuroleptic medication: a validation study of the Italian version of the Drug Attitude Inventory (DAI). Epidemiol Psichiatr Soc. 2001;10(2):107–14. https://doi.org/10.1017/s1121189x00005182 .
doi: 10.1017/s1121189x00005182
pubmed: 11526792
Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312(7027):345–9. https://doi.org/10.1136/bmj.312.7027.345 .
doi: 10.1136/bmj.312.7027.345
pubmed: 8611831
pmcid: 2350295
WMA. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. doi: https://doi.org/10.1001/jama.2013.281053 .
StataCorp. Stata Statistical Software. Release 15.1 ed. College Station, TX: StataCorp LP; 2017.
Decuypere F, Sermon J, Geerts P, Denee TR, De Vos C, Malfait B, et al. Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: a retrospective database study. PLoS ONE. 2017;12(6):e0179049. https://doi.org/10.1371/journal.pone.0179049 .
doi: 10.1371/journal.pone.0179049
pubmed: 28614404
pmcid: 5470699
Deslandes PN, Ward EH, Norris K, Sewell RD. Effectiveness of paliperidone long-acting injection in clinical practice. Ther Adv Psychopharmacol. 2018;8(5):139–45. https://doi.org/10.1177/2045125317753332 .
doi: 10.1177/2045125317753332
pubmed: 29713451
pmcid: 5896863
Whale R, Pereira M, Cuthbert S, Fialho R. Effectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatment: a 12-month naturalistic cohort study. J Clin Psychopharmacol. 2015;35(5):591–5. https://doi.org/10.1097/jcp.0000000000000385 .
doi: 10.1097/jcp.0000000000000385
pubmed: 26267419
Attard A, Olofinjana O, Cornelius V, Curtis V, Taylor D. Paliperidone palmitate long-acting injection–prospective year-long follow-up of use in clinical practice. Acta Psychiatr Scand. 2014;130(1):46–51. https://doi.org/10.1111/acps.12201 .
doi: 10.1111/acps.12201
pubmed: 24117209
Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand. 2006;114(1):14–20. https://doi.org/10.1111/j.1600-0447.2006.00766.x .
doi: 10.1111/j.1600-0447.2006.00766.x
pubmed: 16774656
Deslandes PN, Lewis A, Thomas A, Sewell RD. Risperidone long acting injection: findings of a 2-year retrospective follow-up study. Int J Psychiatry Clin Pract. 2009;13(4):298–302. https://doi.org/10.3109/13651500903046286 .
doi: 10.3109/13651500903046286
pubmed: 24916940
Lammers L, Zehm B, Williams R. Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada. BMC Psychiatry. 2013;13:155. https://doi.org/10.1186/1471-244x-13-155 .
doi: 10.1186/1471-244x-13-155
pubmed: 23718192
pmcid: 3669627
Pilon D, Alcusky M, Xiao Y, Thompson-Leduc P, Lafeuille MH, Lefebvre P, et al. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics. J Med Econ. 2018;21(2):135–43. https://doi.org/10.1080/13696998.2017.1379413 .
doi: 10.1080/13696998.2017.1379413
pubmed: 28895766
Rittmannsberger H, Rosenleitner J, Malsiner-Walli G, Werl R, Rittmannsberger B, Yazdi K. Treatment duration with long-acting injectable antipsychotics after in-hospital initiation: a retrospective cohort study. J Clin Psychopharmacol. 2017;37(2):250–4. https://doi.org/10.1097/jcp.0000000000000672 .
doi: 10.1097/jcp.0000000000000672
pubmed: 28195930
Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry. 2009;70(2):196–200.
doi: 10.4088/JCP.08m04427
Taylor DM, Sparshatt A, O’Hagan M, Dzahini O. Paliperidone palmitate: factors predicting continuation with treatment at 2 years. Eur Neuropsychopharmacol. 2016;26(12):2011–7. https://doi.org/10.1016/j.euroneuro.2016.09.638 .
doi: 10.1016/j.euroneuro.2016.09.638
pubmed: 27743760
Taylor DM, Young C, Patel MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol. 2006;9(6):685–94. https://doi.org/10.1017/s1461145705006309 .
doi: 10.1017/s1461145705006309
pubmed: 16939663